doing via the traditional route of growing cannabis for 10-15 weeks and then extracting the cannabinoids via ethanol or CO2 methodologies. Organigram’s CEO Greg Engel said recently that "Hyasynth's technology offers us access to the future of cannabinoid production today." It is understood that with the disruptive technology that Hyasynth brings to the table that Organigram will now be able to produce pure THC, CBG, and CBD as well as other sub cannabinoids at pennies on the dollar versus plant-based growing methodologies currently in place. On top of that, Engel says that this can be infinitely scalable relative to the 100,000 and 1,000,000 square foot cannabis facilities we are seeing today.
More on the future of cannabinoid production:
Hyasynth's disruptive technology will allow for Organigram to mass-produce pure cannabinoids and minor cannabinoids. Minor cannabinoids will be available to be developed in a controlled environment which would ignore the concern of pesticides that people have surrounding plant grown derivatives as well as allow for specific derivatives to be formulated so that only certain properties are produced. This is precisely what is needed for large scale pharmaceutical use within the medical cannabis space. With this technology and the research and development that goes behind it, specific variants and formulations can be controlled and created, isolating other unwanted properties that may be found when deriving from the plant base source.
24